12 years ago we coined the term ‘oligoprogression’ describing ‘weeding the garden’ with SBRT/SRS for this scenario on targeted therapy in lung cancer. Although there were initial haters, they came round. This is our new update, but it’s way beyond CU now. advancesradonc.org/article/S2452-…

Important open-access article for patients with actionable mutations/fusions #NSCLC --Bravo to CU Anschutz Medical Campus D. Ross Camidge Tejas Patil and #radonc colleagues at #UCDenver advancesradonc.org/article/S2452-…

#LungCancer data at #AACR24 : Dana-Farber's Pasi Jänne, MD, PhD, reports on ctDNA with an EGFR mutation in FLAURA2 trial. The new data shows patients whose blood tested positive before therapy for tumor cell DNA with EGFR mutations stood to gain the most from combination therapy.

Eric K. Singhi, MD Stephen V Liu, MD EGFR Resisters Exon 20 Group, a multi-stakeholder organization Jill Feldman Aakash Desai, MD, MPH LungCancerRx 🫁💊 Sandip Patel MD Narjust Florez, MD, FASCO Dr. Estela Rodriguez So true

But it’s tough to get derm consults in community

You end up being the Oncologist + Dermatologist ( like we do for Cetux )

How to treat advanced NSCLC without driver mutations. First and second line . All IO drugs combinations . Nice tables for quick reference in clinical practice. Check contraindications for bevacizumab. ASCO Journal of Clinical Oncology

Just out CA: A Cancer Journal for Clinicians

'Global cancer statistics 2022: #GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries'

Global maps showing the most common type of cancer mortality among men and women 👇

Lung cancer shown in Blue

American Cancer Society

🚨Our collaborative effort to characterize #MET kinase domain mutations as novel & targetable alterations in #NSCLC and other cancer types is out in Cancer Discovery! Led by💫scientists Federica Pecci & Seshiru Nakazawa
Dana-Farber News OncoAlert #LCSM
shorturl.at/huRT2 1/4🧵

Published in Cancer Discovery ahead of #AACR24 our vision for pushing the boundaries of #liquidbiopsies through transformative technologies and clinical implementation for early precision intervention.
Victor Velculescu Johns Hopkins Thoracic Oncology AACR
doi.org/10.1158/2159-8…

Proud to work with LUNGevity Foundation & team to develop a discussion guide for biomarker testing for patients with solid tumors.

Learn more here: lungevity.org/biomarkerdiscu…

#patienteducation #lcsm

Join us virtually April 11-12 for this MedscapeLIVE NSCLC conference! Comprehensive updates & live Q&A led by co-chairs Drs. Charu Aggarwal, MD, MPH, FASCO Tina Cascone I.DagogoJackMD Benjamin Levy Zosia Piotrowska and dynamic engaging speakers! #PLCClive24

Register at ms.spr.ly/6012c3H8A

💥Just published in light of AACR Annual Meeting #AACR24
🥁Our paper unveils a transformative 'Vision for democratizing Next-Generation Oncology Clinical Trials'
🙌Let's unite researchers, clinicians, patients & policymakers to make trials more inclusive & accessible. Together,

Great news for #HER2 patients across the country. Now let’s please have regulatory agencies beyond the U.S. quickly follow the FDA Oncology lead. #LCSM

New MDPI
🌔MOON: International RWD 🌎 on #mobocertinib in #EGFR Exon20 #lungcancer
✅efficacy pre/post #amivantamab
🔬postprogression analysis
🚺7x more likely to stop due to AE

doi.org/10.3390/ijms25…
Exon 20 Group, a multi-stakeholder organization OncoAlert EGFR Resisters EGFRm NSCLC

🚨Hot of the press MDPI
RWD registry about mobocertinib activity in Ex20EGFR-mutated NSCLC
🧠 activity, mechanism of resistance, AEs
very happy to participate to this excellent work led by Oliver Illini
Exon 20 Group, a multi-stakeholder organization #LCMC
x.com/OliverIllini/s…

Lung cancer in never-smokers represent the 5thleading cause of cancer-related mortality in the world. They are highly enriched for targetable oncogenic alterations, have low TMB, low rates of PD-L1 positivity, & lack mutational signatures. They occur almost exclusively as

#ASCO Educational Book with
Stephanie Saw Jordi Remon Lizza Hendriks
Look forward to this year's ASCO educational sessions.
EGFR Resisters Exon 20 Group, a multi-stakeholder organization MD Anderson Cancer Center

Cont.

3 / 4

📌 Ras pathway 📌

📌 Others 📌

🔈 End….🙇

Cont.

3 / 4

📌 fusions 📌

📌 Ras pathway 📌

Cont.

2 / 4

📌 EGFR 📌

📌 HER2 / HER3 / TROP2 📌

📌 MET 📌

🌟 Updated Oncology Drug List, Ver.2 🌟

💥 Lung - NSCLC & Solid tumors 💥

🧬 Oncogene-driven Target Therapies 🧬

1 / 4

📌 EGFR 📌